A review in the Journal of Bone and Joint Surgery sets the evidence for robotic-assisted joint replacement against the enthusiasm for it. On the technical claim, the evidence is consistent: robotic assistance improves the precision and reproducibility of component positioning.
On the clinical claim, it is not. Systematic reviews, meta-analyses, randomised trials and national registry data have not shown consistent improvement in patient-reported outcomes, complication rates or implant survivorship. The authors attribute the gap to statistical fragility in the positive studies, heterogeneity between platforms that makes pooling questionable, and a disconnect between what the literature supports and what patients have come to expect. They suggest future value may lie in coupling robotics to large-scale data capture and personalisation - and say plainly that this remains unproven.
The practical consequence is about consent and about capital. A patient asking for a robotic knee is asking for something that will be positioned more accurately and is not known to feel better, last longer or go wrong less often; that is what they should be told, in those terms. For a department deciding whether to buy, the question the review poses is whether the outcome data justify the cost - which in Indian practice, where the premium is usually borne by the patient directly, is a sharper question than in a subsidised system.
- Tell patients requesting robotic surgery that precision gains have not translated into better outcomes
- Do not quote implant survivorship or complication benefits - registries have not shown them
- Judge the technology on cost per outcome gained, not on alignment accuracy
- Treat single positive trials with caution; fragility is the named weakness of this literature
- Where the patient is paying the premium themselves, put the uncertainty in the consent conversation
Why it matters
Patients are now requesting this by name, and the consent conversation has been running ahead of the evidence.
Don't overread it
This is a narrative review of existing evidence, not a new trial; absence of demonstrated benefit is not proof that none exists.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for orthopaedics, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free